ChemoCentryx Inc. said on Friday the U.S. health agency approved the company’s lead drug for treating a rare, fatal autoimmune disease, sending the biopharmaceutical company’s shares up by more than 70 percent.
https://www.pharmalive.com/wp-content/uploads/2020/12/Moderna-nears-U.S.-authorization-for-COVID-19-shot-with-FDA-staff-endorsement-Reuters-12-15-20.jpeg246370Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2021-10-08 09:23:282021-10-08 13:06:07ChemoCentryx’s drug gets U.S. FDA nod for treating rare autoimmune disease